Journal
PHARMACOGENOMICS
Volume 15, Issue 8, Pages 1133-1145Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.14.80
Keywords
5-fluorouracil; gemcitabine; pancreatic cancer; SLC transporters; toxicity; treatment response
Categories
Funding
- Czech Science Foundation [P301/12/1734]
- research project Biomedreg [CZ.1.05/2.1.00/01.0030]
Ask authors/readers for more resources
Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Decreased drug transport into tumor cells that may be caused by low expression of membrane proteins, such as solute carrier transporters, represents one of the principal mechanisms of chemotherapy resistance. Individual diversity of multidrug resistance is the major challenge limiting the success of anticancer treatment. Novel biomarkers and pharmacogenomic approaches could further optimize treatment algorithms leading to better survival and lower treatment toxicity in PDAC patients. In this review, the most promising predictive biomarkers from the solute carrier transporter family of membrane transporters and the potential applications for PDAC therapy with nucleoside analogues are summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available